CN109069490A - 痴呆症治疗药或预防药 - Google Patents
痴呆症治疗药或预防药 Download PDFInfo
- Publication number
- CN109069490A CN109069490A CN201780024366.4A CN201780024366A CN109069490A CN 109069490 A CN109069490 A CN 109069490A CN 201780024366 A CN201780024366 A CN 201780024366A CN 109069490 A CN109069490 A CN 109069490A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- base
- formic acid
- thiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016030048 | 2016-02-19 | ||
JP2016-030048 | 2016-02-19 | ||
PCT/JP2017/006007 WO2017142091A1 (ja) | 2016-02-19 | 2017-02-17 | 認知症治療薬または予防薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109069490A true CN109069490A (zh) | 2018-12-21 |
CN109069490B CN109069490B (zh) | 2021-07-16 |
Family
ID=59625278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780024366.4A Active CN109069490B (zh) | 2016-02-19 | 2017-02-17 | 痴呆症治疗药或预防药 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11344539B2 (zh) |
EP (1) | EP3417858B8 (zh) |
JP (1) | JP6732004B2 (zh) |
CN (1) | CN109069490B (zh) |
AR (1) | AR107661A1 (zh) |
ES (1) | ES2842577T3 (zh) |
TW (1) | TWI752007B (zh) |
WO (1) | WO2017142091A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108715601B (zh) * | 2018-05-24 | 2021-07-20 | 华南理工大学 | 一种同时具有抗氧化和抑制Aβ42聚集特性的多肽及其应用与编码该多肽的基因 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0513379A1 (en) * | 1990-11-30 | 1992-11-19 | Teijin Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
CN1596110A (zh) * | 2001-10-29 | 2005-03-16 | 韩国科学技术研究院 | 仙人掌提取物和由其分离的化合物在保护神经细胞中的应用 |
WO2016017699A1 (ja) * | 2014-07-30 | 2016-02-04 | 帝人ファーマ株式会社 | アゾールカルボン酸誘導体 |
CA2955577A1 (en) * | 2014-07-30 | 2016-02-04 | Teijin Pharma Limited | Xanthine oxidase inhibitor |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1379525E (pt) | 2001-02-21 | 2007-12-04 | Astrazeneca Ab | Compostos heteropolicíclicos e sua utilização como antagonistas dos receptores metabotrópicos de glutamato |
DE10149370A1 (de) * | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
JP2003201255A (ja) | 2001-11-05 | 2003-07-18 | Otsuka Pharmaceut Factory Inc | アルツハイマー病予防および治療剤 |
JP2006522164A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−5のジアリール置換ピラゾール修飾因子 |
US7067659B2 (en) * | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
CA2617248C (en) | 2005-08-03 | 2015-09-29 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
US20100112048A1 (en) | 2006-01-24 | 2010-05-06 | Majid Fotuhi | Dosage Regimen and Medicament For Reducing Risk of Onset or Progression of Dementia by Administration of Specific Vitamins and Nsaid |
US8318792B2 (en) * | 2006-07-19 | 2012-11-27 | Nippon Medical School Foundation | Therapeutic agent for amyotrophic lateral sclerosis |
WO2008064015A1 (en) | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
CN101575335B (zh) | 2009-03-05 | 2011-03-16 | 温州医学院 | 间氯苯甲酰基取代脱氢水飞蓟宾及其制备方法和药物用途 |
US20140228417A1 (en) * | 2011-10-05 | 2014-08-14 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
TW201328692A (zh) | 2011-10-11 | 2013-07-16 | Univ Osaka | 脫髓鞘疾病之治療劑及預防劑 |
JP5924699B2 (ja) | 2012-01-27 | 2016-05-25 | 帝人ファーマ株式会社 | 糖尿病の治療薬 |
TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
NO2980085T3 (zh) | 2013-03-29 | 2018-08-11 | ||
WO2017081609A1 (en) | 2015-11-09 | 2017-05-18 | Morningside Ventures Limited | Methods and compositions for promoting adult neurogenesis |
-
2017
- 2017-02-17 JP JP2018500240A patent/JP6732004B2/ja active Active
- 2017-02-17 US US15/998,949 patent/US11344539B2/en active Active
- 2017-02-17 ES ES17753345T patent/ES2842577T3/es active Active
- 2017-02-17 CN CN201780024366.4A patent/CN109069490B/zh active Active
- 2017-02-17 AR ARP170100407A patent/AR107661A1/es unknown
- 2017-02-17 WO PCT/JP2017/006007 patent/WO2017142091A1/ja active Application Filing
- 2017-02-17 EP EP17753345.2A patent/EP3417858B8/en active Active
- 2017-02-18 TW TW106105469A patent/TWI752007B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0513379A1 (en) * | 1990-11-30 | 1992-11-19 | Teijin Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
CN1596110A (zh) * | 2001-10-29 | 2005-03-16 | 韩国科学技术研究院 | 仙人掌提取物和由其分离的化合物在保护神经细胞中的应用 |
WO2016017699A1 (ja) * | 2014-07-30 | 2016-02-04 | 帝人ファーマ株式会社 | アゾールカルボン酸誘導体 |
CA2955577A1 (en) * | 2014-07-30 | 2016-02-04 | Teijin Pharma Limited | Xanthine oxidase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
ES2842577T3 (es) | 2021-07-14 |
EP3417858B1 (en) | 2020-10-28 |
AR107661A1 (es) | 2018-05-23 |
TWI752007B (zh) | 2022-01-11 |
TW201740939A (zh) | 2017-12-01 |
JPWO2017142091A1 (ja) | 2018-12-13 |
WO2017142091A1 (ja) | 2017-08-24 |
CN109069490B (zh) | 2021-07-16 |
US11344539B2 (en) | 2022-05-31 |
JP6732004B2 (ja) | 2020-07-29 |
EP3417858A1 (en) | 2018-12-26 |
US20210205285A1 (en) | 2021-07-08 |
EP3417858A4 (en) | 2019-03-27 |
EP3417858B8 (en) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Takahashi et al. | Plaque formation and the intraneuronal accumulation of β‐amyloid in Alzheimer's disease | |
Ramos-Rodriguez et al. | Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice | |
Lopez et al. | Increased intraneuronal resting [Ca2+] in adult Alzheimer’s disease mice | |
Oddo et al. | Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease: a link between Aβ and tau pathology | |
JP7419486B2 (ja) | τリン酸化を阻害する方法 | |
Upadhaya et al. | High‐molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain | |
KR101591206B1 (ko) | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 | |
Niidome et al. | Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity | |
Blazquez-Llorca et al. | Abnormal tau phosphorylation in the thorny excrescences of CA3 hippocampal neurons in patients with Alzheimer's disease | |
FR2929851A1 (fr) | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules | |
Congdon et al. | Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy | |
Roher et al. | Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy | |
JP6061677B2 (ja) | 薬理シャペロンを用いてガングリオシドの活性を増大させて、アルツハイマー病を治療するための方法 | |
Religa et al. | Amyloid β pathology in Alzheimer’s disease and schizophrenia | |
CN109069490A (zh) | 痴呆症治疗药或预防药 | |
Li et al. | Seeding, maturation and propagation of amyloid β-peptide aggregates in Alzheimer’s disease | |
CN107427517A (zh) | 用于痴呆症的预防及/或治疗的医药 | |
Rabinovich-Nikitin et al. | Beneficial effect of antibodies against β-secretase cleavage site of APP on Alzheimer’s-like pathology in triple-transgenic mice | |
Wang et al. | APOE-ε4 synergizes with sleep disruption to accelerate Aβ deposition and Aβ-associated tau seeding and spreading | |
Savioz et al. | A study of Aβ oligomers in the temporal cortex and cerebellum of patients with neuropathologically confirmed Alzheimer's disease compared to aged controls | |
Siegel et al. | Tomoregulin‐2 is found extensively in plaques in Alzheimer's disease brain | |
CN103237802B (zh) | 2‑(R2‑硫代)‑10‑[3‑(4‑R1‑哌嗪‑1‑基)丙基]‑10H‑吩噻嗪用于治疗β‑淀粉样病或α‑共核蛋白病以及诊断或前诊断它们的方法 | |
Stoll et al. | Long-term transplants of mouse trisomy 16 hippocampal neurons, a model for Down's syndrome, do not develop Alzheimer's disease neuropathology | |
Nishimura et al. | RS‐4252 Inhibits Amyloid β‐Induced Cytotoxicity in HeLa Cells | |
WO2004028540A1 (ja) | 抗神経変性薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190412 Address after: Japan's Birds Choose County Birds to Choose Market Applicant after: NATIONAL UNIVERSITY CORPORATION TOTTORI University Applicant after: NIPPON MEDICAL SCHOOL FOUNDATION Applicant after: Nishino Takeshi Address before: Japan's Birds Choose County Birds to Choose Market Applicant before: NATIONAL UNIVERSITY CORPORATION TOTTORI University Applicant before: NIPPON MEDICAL SCHOOL FOUNDATION Applicant before: TEIJIN PHARMA Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40001864 Country of ref document: HK |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201125 Address after: 3 / F, building 1, No. 400 Fangchun Road, Pudong New Area (Shanghai) pilot Free Trade Zone, Shanghai Applicant after: Shanghai gennaijin Pharmaceutical Technology Co.,Ltd. Address before: Japan's Birds Choose County Birds to Choose Market Applicant before: NATIONAL UNIVERSITY CORPORATION TOTTORI University Applicant before: Nishino Takeshi Applicant before: Okamoto Effective date of registration: 20201125 Address after: Japan's Birds Choose County Birds to Choose Market Applicant after: NATIONAL UNIVERSITY CORPORATION TOTTORI University Applicant after: Nishino Takeshi Applicant after: Okamoto Address before: Japan's Birds Choose County Birds to Choose Market Applicant before: NATIONAL UNIVERSITY CORPORATION TOTTORI University Applicant before: NIPPON MEDICAL SCHOOL FOUNDATION Applicant before: Nishino Takeshi |
|
GR01 | Patent grant | ||
GR01 | Patent grant |